The timeline of epigenetic drug discovery: from reality to dreams.

Abstract excerpt

The flexibility of the epigenome has generated an enticing argument to explore its reversion through pharmacological treatments as a strategy to ameliorate disease phenotypes. All three families of epigenetic proteins-readers, writers, and erasers-are druggable targets that can be addressed through small-molecule inhibitors. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Structure
• Share to Phenotype
• Share to Clinical Trials as Topic